129TiP: SAKK 16/14 - anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC): a multicenter single-arm phase II trial

S.I. Rothschild1, A. Zippelius1, S. Savic Prince2, M. Gonzalez3, W. Weder4, A. Xyrafas5, C. Rusterholz5, M. Pless6. 1Medical Oncology, Universitatsspital Basel, Basel, Switzerland , 2 Institute of Pathology, Universitatsspital Basel, Basel, Switzerland, 3 Service de Chirurgie Thoracique, Centre Hospitalier Universitaire Vaudois – CHUV, Lausanne, Switzerland, 4 Division of Thoracic Surgery, Universitatsspital Zurich, Zurich, Switzerland, 5 Swiss Group for Clinical Cancer Research, SAKK, Bern, Switzerland, 6 Tumorcenter, Kantonsspital Winterthur, Winterthur, Switzerland